Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
21.90
-0.03 (-0.14%)
Dec 5, 2025, 4:00 PM EST - Market closed
Evommune Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 3 | 7 | 5 |
| Revenue Growth (YoY) | - | 40.00% | - |
| Gross Profit | 3 | 7 | 5 |
| Selling, General & Admin | 13.88 | 12.77 | 10.85 |
| Research & Development | 65.12 | 64.24 | 32 |
| Operating Expenses | 79 | 77.01 | 42.85 |
| Operating Income | -76 | -70.01 | -37.85 |
| Interest Expense | -0.02 | -0.03 | -0.06 |
| Interest & Investment Income | 2.36 | 3.24 | 3.86 |
| Other Non Operating Income (Expenses) | 8.89 | -0 | -0 |
| Pretax Income | -64.76 | -66.81 | -34.05 |
| Net Income | -64.76 | -66.81 | -34.05 |
| Preferred Dividends & Other Adjustments | 1.5 | 1.5 | - |
| Net Income to Common | -66.26 | -68.31 | -34.05 |
| Shares Outstanding (Basic) | 13 | 13 | 11 |
| Shares Outstanding (Diluted) | 13 | 13 | 11 |
| Shares Change (YoY) | - | 20.35% | - |
| EPS (Basic) | -5.15 | -5.32 | -3.19 |
| EPS (Diluted) | -5.15 | -5.32 | -3.19 |
| Free Cash Flow | -94.85 | -58.28 | -30.09 |
| Free Cash Flow Per Share | -7.37 | -4.54 | -2.82 |
| Gross Margin | 100.00% | 100.00% | 100.00% |
| Operating Margin | -2533.20% | -1000.19% | -757.00% |
| Profit Margin | -2208.80% | -975.83% | -681.06% |
| Free Cash Flow Margin | -3161.53% | -832.61% | -601.76% |
| EBITDA | -74.55 | -68.73 | -36.85 |
| D&A For EBITDA | 1.44 | 1.29 | 1 |
| EBIT | -76 | -70.01 | -37.85 |
| Revenue as Reported | 7 | 7 | 5 |
Source: S&P Capital IQ. Standard template.
Financial Sources.